VRTX
Vertex Pharmaceuticals Incorporated
Biotechnology · Healthcare · United States
516.44
close · 2026-08-13
value
45
cheaper than peers45
quality
87
stronger fundamentals87
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 9.65× | 60 |
| EV to EBITDA | 22.23× | 53 |
| price to book | 6.46× | 42 |
| forward P/E | 23.69× | 40 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 38.1% | 91 |
| return on equity | 23.5% | 85 |
| debt to equity | 9.8% | 65 |
| revenue growth | 12.5% | 35 |
4 of 4 measures available
Facts
| market cap | $131B |
| free cash flow | — |
| employees | 6,400 |
| first trade | 1991-07-24 |
| next earnings | 2026-08-03 |
| fundamentals updated | 2026-08-04 |